-
Verapamil has uncertain C-peptide effect in type 1 diabetes
25 Sep 2025 16:19 GMT
… stage 3 type 1 diabetes.
“Verapamil is known as a drug that [ … with new-onset type 1 diabetes to participate in the trial (mean age … test.
Trial outcomes
In the intention-to-treat analysis, … than 3 years after treatment initiation.
Pieber also suggested …
-
Oxford University to accelerate type 1 diabetes research and care with £10 million gift
25 Sep 2025 09:29 GMT
… tens of millions worldwide. Current treatment relies on insulin replacement through … historic period for type 1 diabetes care since insulin therapy was developed over 100 … in accelerating progress towards new treatments and, ultimately, a future where …
-
ixlayer Survey Reveals 94% of Pharma Leaders Currently or Plan to Run Direct-to-Consumer Programs Within the Next Year
25 Sep 2025 23:27 GMT
… from its survey of pharmaceutical industry leaders, conducted … and accelerating time to treatment," said Debra Harris, … revealed pharma leaders’ belief that accelerated time to treatment is … way. In a recent Type 1 diabetes program, every patient screened …
-
Scientists outline how future therapies could change type 1 diabetes care
24 Sep 2025 22:24 GMT
… a new era of type 1 diabetes treatment is emerging, but only … future clinical translation in type 1 diabetes.
Background
One diagnosis, … States Food and Drug Administration (FDA) approval of teplizumab … example, the PROTECT trial) shows preservation of meal …
-
EASD/ADA Draft Updates Type 1 Diabetes Management Guidance
24 Sep 2025 11:06 GMT
… the 2021 guidance on managing type 1 diabetes (T1D) in adults, … when not meeting treatment targets, when complications develop, or when … RA) and SGLT2 inhibitor drugs for CV risk management, … advisory board for Vertex Pharmaceuticals and Medscape and receiving …
-
New ixlayer Survey Finds 73% of Pharma Leaders Are Running or Planning to Launch a DTP Program in the Next Year, and Half Say DTP Will Be Standard Practice Within Five Years
25 Sep 2025 14:49 GMT
… survey of pharmaceutical leaders include:
94% of pharma are either … and accelerating time to treatment," said Debra Harris, … : patients, physicians and pharma. All three voices converge … "In a recent Type 1 diabetes program, every patient screened …
-
Assessing Vertex Pharmaceuticals: Insights From 15 Financial Analysts
25 Sep 2025 12:36 GMT
… Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment … non-opioid pain medication approved for the treatment of moderate-to … cure for type 1 diabetes.
A Deep Dive into Vertex Pharmaceuticals';s …
-
After FDA Rejection, Lexicon’s Type 1 Diabetes Drug Hit With Another Regulatory Delay
23 Sep 2025 12:59 GMT
… additional submissions for the drug.
Following a complete … the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee … type 1 diabetes do not outweigh its risks, according to reporting from Fierce Pharma … -stage trial. The Phase IIb PROGRESS trial focused …
-
Pill Effective In Slowing Type 1 Diabetes Progression
23 Sep 2025 10:39 GMT
… (HealthDay News) — A pill typically prescribed for rheumatoid arthritis … is already approved for treating autoimmune conditions such as … daily baricitinib or placebo pills for 48 weeks.
… , the drug could be approved for type 1 diabetes treatment within five …
-
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
22 Sep 2025 20:00 GMT
… in adults with type 1 diabetes (T1D). The FDA has informed … -trial/. Accessed 4 Sept. 2025. About Lexicon Pharmaceuticals … and development of innovative medicines to treat disease … potential of its other drug candidates, including sotagliflozin. …
About
© 1995-2025